Despite recent approvals of drugs targeting acute myeloid leukemia (AML), overall survival and complete remission rates remain suboptimal. In this interview, Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains how he encourages his AML patients to participate in clinical trials, especially those who are in a relapsed or refractory state. Patients are more hesitant to participate in randomized, placebo-controlled trials because there is no guarantee that they will receive the active drug, and due to the general commitments associated with trial participation. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Encouraging patients to participate in AML trials
